Actinogen Medical — XanaMIA passes first safety milestone
Actinogen Medical reported that the independent Data Monitoring Committee (DMC) of the company’s pivotal Phase IIb/III XanaMIA study in patients...
163 Views
Actinogen Medical — XanaMIA recruitment exceeds expectations
Actinogen Medical reported that, due to recent accelerations in screening and enrolment for its Phase IIb/III XanaMIA study of lead candidate...
205 Views
Actinogen Medical — An eventful period ahead for Xanamem
Actinogen’s FY25 results highlighted the company’s progress in advancing its lead candidate, Xanamem, through its pivotal XanaMIA Phase IIb/III...
263 Views
Actinogen Medical — XanaMIA study enrols 100th patient
Actinogen Medical announced on 30 June that it has recruited the 100th patient for its ongoing XanaMIA Phase IIb/III study assessing lead candidate...
296 Views
Actinogen Medical — XanaMIA study enrols 100th patient
Actinogen Medical announced on 30 June that it has recruited the 100th patient for its ongoing XanaMIA Phase IIb/III study assessing lead candidate...
251 Views